Prof. Dr. med. habil. Jochen G. Mainz

Prof. Dr. med. habil. Jochen G. Mainz
Oberarzt - Leiter Päd. Pneumologie, Mukoviszidose

Prof. Dr. med. habil. Jochen G. Mainz
OA, Leiter Päd. Pneumologie, Allergologie, Mukoviszidosezentrum
Klinikum Westbrandenburg, Klinik für Kinder- und Jugendmedizin,
Hochstraße 29,
14770 Brandenburg an der Havel

Sekretariat: (03381) 41 1841

Mukoviszidosezentrum Brandenburg an der Havel


Telefon: (03381) 41 18 41
E-Mail: j.mainz@uk-brandenburg.de
Publikationen

Für eine Übersicht aller Publikationen nutzen Sie bitte diesen Link.

Versorgungsforschung bei Mukoviszidose (Auswahl)

•Bell SC, Mainz JG, MacGregor G, Madge S, Macey J, Fridman M, Suthoff ED, Narayanan S, Kinnman N. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study. BMC Pulm Med. 2019 Aug 13;19(1):146. doi: 10.1186/s12890-019-0887-6.
•    Narayanan S, Mainz JG, Gala S, Tabori H, Grossoehme D. Adherence to therapies in cystic fibrosis: a targeted literature review. Expert Rev Respir Med. 2017 Feb;11(2):129-145. doi: 10.1080/17476348.2017.1280399. Epub 2017 Jan 20. Review.

Abdominelle Beschwerden bei Mukoviszidose
 
•    Jaudszus A, Zeman E, Jans T, Pfeifer E, Tabori H, Arnold C, Michl RK, Lorenz M, Beiersdorf N, Mainz JG. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).  Patient. 2019 Aug;12(4):419-428. doi: 10.1007/s40271-019-00361-2.
•    Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, Lorenz M, Michl R, Gerber A, Lehmann T, Mainz JG. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017 May 4;12(5):e0174463. doi: 10.1371/journal.pone.0174463. eCollection 2017.
•    Tabori H, Jaudszus A, Arnold C, Mentzel HJ, Lorenz M, Michl RK, Lehmann T, Renz DM, Mainz JG. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients. Sci Rep. 2017 Dec 12;7(1):17465. doi: 10.1038/s41598-017-17302-4.

Beteiligung der oberen Atemwege und Nasennebenhöhlen bei Mukoviszidose (Auswahl)
 
•    Morlacchi LC, Greer M, Tudorache I, Blasi F, Welte T, Haverich A, Mainz JG*, Gottlieb J.* The burden of sinus disease in cystic fibrosis lung transplant recipients. Transpl Infect Dis. 2018 Oct;20(5):e12924. doi: 10.1111/tid.12924. Epub 2018 Jun 28.
•    Mainz JG, Schumacher U, Schädlich K, Hentschel J, Koitschev C, Koitschev A, Riethmüller J, Prenzel F, Sommerburg O, Wiedemann B, Staab D, Gleiber W, Fischer R, Beck JF, Arnold C; Cooperators. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial. J Cyst Fibros. 2016  
•    Bock J, Schien M, Gerber A, Naehrlich L, Kaeding M, Guntinas-Lichius O, Arnold, C, Mainz JG  Importance to question sinonasal symptoms and to perform rhinoscopy and rhinomanometry in cystic fibrosis patients.              Pediatr Pulmonol. 2017 Feb;52(2):167-174
•    Mainz JG, Schädlich K, Schien C, Schelhorn-Neise P, Koitschev A, Keller P, Riethmüller J, Wiedemann B, Beck JF - Sinonasal inhalation of Tobramycin in CF-patients with P.aeruginosa-colonization of the upper airways - results of a multicentric placebo controlled pilot study Drug Design, Development and Therapy 2014:8 209–217
•    Hentschel J, Müller U, Doht F, Fischer N, Böer K, Sonnemann J, Hipler U-C, Hünniger K, Kurzai O, Markert UR, Mainz JG - Influences of nasal lavage collection-, processing- and storage methods on inflammatory markers  - Evaluation of a method for non-invasive sampling of epithelial lining fluid in cystic fibrosis and other respiratory diseases. Journal of Immunological Methods             12/2013; DOI:10.1016/j.jim.2013.12.003  (in press)
•    Michl RK, Fischer C, Beck JF, Mainz JG  -Reduced Nasal Nitric Oxide in Cystic Fibrosis Patients with Elevated Systemic Inflammation Markers PLoS One. 2013 Nov 13;8(11):e79141. doi: 10.1371/journal.pone.0079141. PMID:24236100
•    Beiersdorf N, Schien M, Hentschel J, Pfister W, Markert U and Mainz JG - Soluble Inflammation Markers in Nasal Lavage from CF-Patients and Healthy Controls, J Cyst Fibros. 2012 Sep 15. doi:pii: S1569-1993(12)00154-3. 10.1016/j.jcf.2012.08.015. [Epub ahead of print]
•    Lindig J, Steger C, Beiersdorf N, Michl R, Beck JF, Hummel T, and Mainz JG - Smell in Cystic Fibrosis, Curr Allergy Asthma Rep. 2012 Apr;12(2):163-74. doi: 10.1007/s11882-012-0250-y.
•    Mainz JG, Hentschel J, Schien C, Cramer N, Pfister W, Beck JF, Tümmler B. - Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation., J Cyst Fibros. 2012 Mar;11(2):158-61. doi: 10.1016/j.jcf.2011.10.009. Epub 2011 Nov 30.
•    Mainz JG, Michl R, Pfister W, Beck JF. - Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1089-90.
•    Mainz JG, Schiller I, Ritschel C, Mentzel H-J, Riethmüller J, Koitschev A, Schneider G, Beck JF, Wiedemann B - Sinonasal inhalation of dornase alfa in CF:a double-blind placebo-controlled cross-over pilot trial. Auris Nasus Larynx. 2011 Apr;38(2):220-7. Epub 2010 Oct 27
•    Mainz JG, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, Schneider G,  Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B - Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis, Thorax 2009;64(6):535-40. Epub 2009 Mar 11.
•    Mainz JG, Koitschev A - Management of chronic rhinosinusitis in CF, Journal of Cystic Fibrosis 2009; 8 S1: 10-14
 
Aktivatoren und Potentiatoren von Chloridkanälen bei CF
 
•    Graeber SY, Hug MJ, Sommerburg O, Hirtz S, Hentschel J, Heinzmann A, Dopfer C, Schulz A, Mainz JG, Tümmler B, Mall MA. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE.
•    Hebestreit H, Sauer-Heilborn S, Fischer R, Käding M, Mainz JG - Effects of Ivacaftor on cystic fibrosis with at least one G551D mutation and poor pulmonary function J Cyst Fibros. 12 (2013) 599–603 pii: S1569-1993(13)00082-9. doi: 10.1016/j.jcf.2013.05.006.
•    Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez C, Ahrens R; on behalf of the VX08-770-103 (ENVISION) Study Group.     Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC

Sonographische Knochenbeurteilung bei Asthma
 
•    Mainz JG, Kaiser WA, Beck JF, Mentzel H-J - Substantially reduced calcaneal bone ultrasound parameters in severe untreated asthma. Respiration 2009; 78(2):230-3. Epub 2009 Feb 21
•    Mainz JG, Sauner D, Malich A, John S, Beyermann H, Mentzel H-J, Kaiser WA, Zintl F - Cross-sectional study on bone density related sonographic parameters in children with asthma - correlation to therapy with inhaled corticosteroids and disease severity. J Bone Miner Metab 2008;26(5):485-92. Epub 2008 Aug 30.